JP2011529054A5 - - Google Patents

Download PDF

Info

Publication number
JP2011529054A5
JP2011529054A5 JP2011520095A JP2011520095A JP2011529054A5 JP 2011529054 A5 JP2011529054 A5 JP 2011529054A5 JP 2011520095 A JP2011520095 A JP 2011520095A JP 2011520095 A JP2011520095 A JP 2011520095A JP 2011529054 A5 JP2011529054 A5 JP 2011529054A5
Authority
JP
Japan
Prior art keywords
acceptable salt
methyl
compound according
pharmaceutically acceptable
morpholin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011520095A
Other languages
English (en)
Japanese (ja)
Other versions
JP5414794B2 (ja
JP2011529054A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/050640 external-priority patent/WO2010011538A1/en
Publication of JP2011529054A publication Critical patent/JP2011529054A/ja
Publication of JP2011529054A5 publication Critical patent/JP2011529054A5/ja
Application granted granted Critical
Publication of JP5414794B2 publication Critical patent/JP5414794B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011520095A 2008-07-24 2009-07-15 C−metの阻害剤として有用なアミドフェノキシインダゾール Expired - Fee Related JP5414794B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8329408P 2008-07-24 2008-07-24
US61/083,294 2008-07-24
US8508208P 2008-07-31 2008-07-31
US61/085,082 2008-07-31
US10865908P 2008-10-27 2008-10-27
US61/108,659 2008-10-27
PCT/US2009/050640 WO2010011538A1 (en) 2008-07-24 2009-07-15 Amidophenoxyindazoles useful as inhibitors of c-met

Publications (3)

Publication Number Publication Date
JP2011529054A JP2011529054A (ja) 2011-12-01
JP2011529054A5 true JP2011529054A5 (cg-RX-API-DMAC10.html) 2012-03-15
JP5414794B2 JP5414794B2 (ja) 2014-02-12

Family

ID=41010247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011520095A Expired - Fee Related JP5414794B2 (ja) 2008-07-24 2009-07-15 C−metの阻害剤として有用なアミドフェノキシインダゾール

Country Status (35)

Country Link
US (2) US8030302B2 (cg-RX-API-DMAC10.html)
EP (1) EP2310382B1 (cg-RX-API-DMAC10.html)
JP (1) JP5414794B2 (cg-RX-API-DMAC10.html)
KR (1) KR101334456B1 (cg-RX-API-DMAC10.html)
CN (1) CN102105462B (cg-RX-API-DMAC10.html)
AR (1) AR074632A1 (cg-RX-API-DMAC10.html)
AT (1) ATE546444T1 (cg-RX-API-DMAC10.html)
AU (1) AU2009274256B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0916286B8 (cg-RX-API-DMAC10.html)
CA (1) CA2731773C (cg-RX-API-DMAC10.html)
CL (1) CL2011000134A1 (cg-RX-API-DMAC10.html)
CO (1) CO6351737A2 (cg-RX-API-DMAC10.html)
CR (1) CR20110046A (cg-RX-API-DMAC10.html)
CY (1) CY1112595T1 (cg-RX-API-DMAC10.html)
DK (1) DK2310382T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2011000009A (cg-RX-API-DMAC10.html)
EA (1) EA018385B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP11010778A (cg-RX-API-DMAC10.html)
ES (1) ES2379587T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20120202T1 (cg-RX-API-DMAC10.html)
IL (1) IL210490A (cg-RX-API-DMAC10.html)
JO (1) JO2788B1 (cg-RX-API-DMAC10.html)
MA (1) MA32594B1 (cg-RX-API-DMAC10.html)
MX (1) MX2011000925A (cg-RX-API-DMAC10.html)
MY (1) MY163852A (cg-RX-API-DMAC10.html)
NZ (1) NZ590013A (cg-RX-API-DMAC10.html)
PE (1) PE20110150A1 (cg-RX-API-DMAC10.html)
PL (1) PL2310382T3 (cg-RX-API-DMAC10.html)
PT (1) PT2310382E (cg-RX-API-DMAC10.html)
RS (1) RS52261B (cg-RX-API-DMAC10.html)
SI (1) SI2310382T1 (cg-RX-API-DMAC10.html)
SV (1) SV2011003816A (cg-RX-API-DMAC10.html)
TW (1) TWI365185B (cg-RX-API-DMAC10.html)
WO (1) WO2010011538A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201100219B (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045095A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
JP5583751B2 (ja) 2009-03-21 2014-09-03 クイ ニング アミノエステル誘導体、その塩、及び使用方法
BR112013014708B1 (pt) 2011-02-28 2021-10-19 Sunshine Lake Pharma Co., Ltd. Composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
WO2012121939A2 (en) * 2011-03-04 2012-09-13 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
ES2641444T3 (es) * 2012-05-09 2017-11-10 Eli Lilly And Company Procedimiento de preparación de cloruros de 4-[[(benzoil)amino]sulfonil]benzoílo y preparación de acilsulfamoilbenzamidas
WO2014134313A1 (en) * 2013-02-27 2014-09-04 Array Biopharma Inc. Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
CN104140393B (zh) * 2013-12-10 2016-09-21 郑州泰基鸿诺医药股份有限公司 一种芳环/芳杂环叔丁醇酯类化合物的制备方法
US9718841B2 (en) 2014-04-22 2017-08-01 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
TW201716085A (zh) * 2015-08-12 2017-05-16 應克隆公司 癌症之組合療法
EP3442573A1 (en) * 2016-04-15 2019-02-20 Eli Lilly and Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
FI3464380T3 (fi) 2016-06-02 2025-01-31 Immunocore Ltd Gp100-spesifisen tcr-anti-cd3 scfv-fuusioproteiinin annosteluohjelma
JP2019525934A (ja) * 2016-07-29 2019-09-12 イーライ リリー アンド カンパニー 癌の治療に使用するためのメレスチニブおよび抗pd−l1または抗pd−1阻害剤を用いた組み合わせ治療
CN108069938A (zh) * 2016-11-15 2018-05-25 中国药科大学 2,4-二取代吡啶类化合物及其制备方法和应用
WO2018093654A1 (en) 2016-11-16 2018-05-24 Eli Lilly And Company Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
ES2866348T3 (es) 2016-11-16 2021-10-19 Lilly Co Eli Terapia de combinación para el cáncer con mutación o mutaciones de omisión del exón 14 o fenotipo de omisión del exón 14
CN107382968A (zh) * 2017-07-06 2017-11-24 北京万全德众医药生物技术有限公司 一种吲哚类c‑Met抑制剂的制备方法
CN107311983A (zh) * 2017-07-06 2017-11-03 北京万全德众医药生物技术有限公司 吲哚类小分子c‑met抑制剂
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
US11623923B2 (en) 2017-11-24 2023-04-11 Medshine Discovery, Inc. Uracil compound as c-MET/AXL inhibitor
US20210177828A1 (en) * 2018-01-17 2021-06-17 Nanjing Transthera Biosciences Co., Ltd. Tam family kinase /and csf1r kinase inhibitor and use thereof
CN111295386B (zh) 2018-03-08 2022-09-06 伟迈可生物有限公司 噻吩并吡啶衍生物及含有该衍生物的药物组合物
SG11202101622VA (en) * 2018-08-24 2021-03-30 Nanjing Transthera Biosciences Co Ltd Novel quinoline derivative inhibitor
EP3848365A4 (en) 2018-09-03 2022-06-01 Tyligand Bioscience (Shanghai) Limited TRK INHIBITORS AS AN ANTI-CANCER AGENT
KR20220059386A (ko) 2019-09-06 2022-05-10 웰마커바이오 주식회사 바이오마커 기반 치료용 조성물
CN117355533A (zh) * 2021-06-22 2024-01-05 株式会社Lg化学 作为蛋白激酶抑制剂的新型化合物
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US5484681A (en) * 1994-10-31 1996-01-16 Xerox Corporation Conductive composite particles and processes for the preparation thereof
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
US5747577A (en) * 1995-12-27 1998-05-05 Xerox Corporation Conductive particles containing carbon black and processes for the preparation thereof
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
CN1258091C (zh) * 2001-05-18 2006-05-31 爱赐爱儿股份有限公司 免疫测定
US6956084B2 (en) * 2001-10-04 2005-10-18 Bridgestone Corporation Nano-particle preparation and applications
JP2004067703A (ja) * 2002-04-24 2004-03-04 Japan Science & Technology Corp 架橋ポリマー、微粒子および製造方法
US7192780B2 (en) * 2002-10-23 2007-03-20 Evident Technologies Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals
WO2004039796A1 (de) 2002-10-28 2004-05-13 Bayer Healthcare Ag Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
EP1649284B1 (en) * 2003-07-17 2007-12-05 Invitrogen Dynal AS Process for preparing coated magnetic particles
US7163998B2 (en) * 2003-09-09 2007-01-16 Eastman Kodak Company Stabilized polymer beads and method of preparation
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
MY159523A (en) 2005-12-21 2017-01-13 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
MX2008011220A (es) * 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
EP2038320B1 (en) * 2006-06-29 2014-03-12 Life Technologies AS Particles containing multi- block polymers
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8507489B2 (en) 2006-10-23 2013-08-13 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
EP2170785B1 (en) 2007-06-27 2018-09-12 Arkema Inc. Process for the manufacture of hydrofluoroolefins

Similar Documents

Publication Publication Date Title
JP2011529054A5 (cg-RX-API-DMAC10.html)
JP2012533546A5 (cg-RX-API-DMAC10.html)
HRP20120202T1 (hr) AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET
JP2014511891A5 (cg-RX-API-DMAC10.html)
JP2013537203A5 (cg-RX-API-DMAC10.html)
JP2016514159A5 (cg-RX-API-DMAC10.html)
JP2012507535A5 (cg-RX-API-DMAC10.html)
JP2019524883A5 (cg-RX-API-DMAC10.html)
JP2014503574A5 (cg-RX-API-DMAC10.html)
JP2012092103A5 (cg-RX-API-DMAC10.html)
JP2015505296A5 (cg-RX-API-DMAC10.html)
JP2011519854A5 (cg-RX-API-DMAC10.html)
JP2014506907A5 (cg-RX-API-DMAC10.html)
JP2015524472A5 (cg-RX-API-DMAC10.html)
JP2011518833A5 (cg-RX-API-DMAC10.html)
JP2011518811A5 (cg-RX-API-DMAC10.html)
JP2015516427A5 (cg-RX-API-DMAC10.html)
JP2014528464A5 (cg-RX-API-DMAC10.html)
JP2017517565A5 (cg-RX-API-DMAC10.html)
JP2013542267A5 (cg-RX-API-DMAC10.html)
JP2017521375A5 (cg-RX-API-DMAC10.html)
JP2014530818A5 (cg-RX-API-DMAC10.html)
JP2016528273A5 (cg-RX-API-DMAC10.html)
JP2013506674A5 (cg-RX-API-DMAC10.html)
JP2012509265A5 (cg-RX-API-DMAC10.html)